Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ruxolitinib for steroid-resistant acute GVHD.

Literature DB >> 32407526

Ruxolitinib for steroid-resistant acute GVHD.

Antonio Maria Risitano¹, Regis Peffault de Latour².

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2020 PMID： 32407526 DOI： 10.1182/blood.2020005364

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

Review 1. JAK inhibitors and COVID-19.

Authors: Gabriel Levy; Paola Guglielmelli; Peter Langmuir; Stefan N Constantinescu
Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469

2. Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

Authors: Molly Mercedes Ryan; Mihir Patel; Keenan Hogan; Ariel Joy Lipat; Rafaela Scandolara; Rahul Das; Charles Bruker; Jacques Galipeau; Raghavan Chinnadurai
Journal: Transplant Cell Ther Date: 2021-02-04

3. TSLP Produced by Aspergillus fumigatus-Stimulated DCs Promotes a Th17 Response Through the JAK/STAT Signaling Pathway in Fungal Keratitis.

Authors: Fang Han; Hui Guo; Leyi Wang; Yuting Zhang; Lin Sun; Chenyang Dai; Xinyi Wu
Journal: Invest Ophthalmol Vis Sci Date: 2020-12-01 Impact factor: 4.799

7. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

Authors: Xiang Liu; Xueling Zhu; Xiaotang Zhou; Yirui Xie; Dairong Xiang; Zhikai Wan; Ying Huang; Biao Zhu
Journal: Front Immunol Date: 2022-10-03 Impact factor: 8.786

7 in total

Ruxolitinib for steroid-resistant acute GVHD.

Review 1. JAK inhibitors and COVID-19.

2. Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

3. TSLP Produced by Aspergillus fumigatus-Stimulated DCs Promotes a Th17 Response Through the JAK/STAT Signaling Pathway in Fungal Keratitis.

Review 4. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

Review 5. Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.

6. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.

7. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.